- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Elevated Troponin Levels may predict mortality among patients with COPD Exacerbations
Chronic Obstructive Pulmonary Disease (COPD) patients facing exacerbations may now have a potential predictive marker for major adverse cardiac events (MACE), according to a recent study conducted across five hospitals in England. While no singular biomarker currently exists for risk stratification during COPD exacerbation, this research focused on the correlation between elevated troponin levels and subsequent adverse outcomes.
Troponin, a cardiac marker, was found to be elevated in 44.5% of the 2487 COPD patients analyzed. Among these individuals, 22.8% experienced a MACE event, and 9.0% were readmitted for COPD within 90 days from peak troponin measurement. The study adjusted for various factors, including age, sex, laboratory results, and clinical risk factors.
Patients with troponin levels exceeding the upper limit of normal demonstrated a significantly higher risk of MACE (adjusted HR 2.20, 95% CI 1.75–2.77) and COPD hospital readmission (adjusted HR 1.37, 95% CI 1.02–1.83) compared to those without elevated troponin. The findings suggest that an elevated troponin level during a COPD exacerbation could serve as a valuable tool for predicting cardiovascular events in COPD patients.
The research underscores the importance of exploring new markers for risk stratification during COPD exacerbation, particularly given the complexity of the disease and its diverse outcomes. While this study provides crucial insights into the potential link between troponin levels and cardiovascular risks, further investigations are needed to understand the nuanced relationship between the degree of troponin elevation and the likelihood of future adverse events. This development opens avenues for enhanced monitoring and tailored interventions for COPD patients, offering a glimpse into a more personalized approach to managing exacerbations and improving overall patient outcomes.
Reference:
Kallis, C., Kaura, A., Samuel, N., Mulla, A., Glampson, B., O’Gallagher, K., Davies, J., Papadimitriou, D., Woods, K., Shah, A., Williams, B., Squire, I., Johnson, T., … Quint, J. (2023). The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions. In International Journal of Chronic Obstructive Pulmonary Disease: Vol. Volume 18 (pp. 2405–2416). Informa UK Limited. https://doi.org/10.2147/copd.s432166
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751